Provided by Tiger Fintech (Singapore) Pte. Ltd.

INCANNEX HEALTHCARE LTD

0.2094
+0.00251.21%
Post-market: 0.20960.0002+0.10%16:59 EDT
Volume:9.26M
Turnover:1.93M
Market Cap:19.62M
PE:-0.17
High:0.2102
Open:0.2100
Low:0.2059
Close:0.2069
Loading ...

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program With Appointment of DR. Douglas B. Kirsch

THOMSON REUTERS
·
24 Jun

Press Release: Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Dow Jones
·
24 Jun

Incannex Healthcare Achieves Key Milestone with Phase 2 Trial Database Lock for First-in-Class OSA Drug, Top-Line Results Expected July 2025

Reuters
·
18 Jun

Incannex Achieves Key Milestone With Database Lock for Reposa Phase 2 Trial of Ihl-42X

THOMSON REUTERS
·
18 Jun

Incannex Healthcare Inc - Top-Line Results Expected in July 2025

THOMSON REUTERS
·
18 Jun

Incannex Healthcare and Mind Medicine Australia Launch Joint Venture for Psychedelic-Assisted Therapy Clinic in Melbourne

Reuters
·
17 Jun

Incannex Healthcare Forms Joint Venture With Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

THOMSON REUTERS
·
17 Jun

Incannex Healthcare Inc - New Entity Mind Medicine Australia Clinics Announced

THOMSON REUTERS
·
17 Jun

Incannex Healthcare Inc - Patient Intake to Begin Shortly Due to Strong Demand

THOMSON REUTERS
·
17 Jun

Incannex Healthcare Inc. Initiates Transfer of Listing to Nasdaq Capital Market to Meet Compliance Requirements

Reuters
·
13 Jun

Incannex cancels all outstanding Series A warrants following ATM execution

TIPRANKS
·
12 Jun

Incannex Healthcare Streamlines Capital Structure, Cancels Series A Warrants Ahead of Key Phase 2 Trial Milestone for IHL-42X in Obstructive Sleep Apnea

Reuters
·
12 Jun

Press Release: Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

Dow Jones
·
03 Jun

Incannex Healthcare Inc. Advances to Phase 3 Clinical Trial for IHL-42X in Obstructive Sleep Apnea Treatment, Following FDA Authorization

Reuters
·
29 May

BRIEF-Incannex Healthcare Advances IHL-42X Reposa Trial To Phase 3 Following FDA Protocol Clearance

Reuters
·
29 May

Incannex Healthcare Inc. Advances Ihl-42X Reposa Trial to Phase 3 Following FDA Protocol Clearance

THOMSON REUTERS
·
29 May

Stonegate Capital Partners Updates Coverage on Incannex Healthcare, Highlights Cost Savings and Financial Improvements

Reuters
·
29 May

Incannex Healthcare Cancels Series A Warrants, Eliminates Potential Dilution of 347 Million Shares Ahead of Key Trial Results

Reuters
·
28 May

Incannex Healthcare Inc - Increases Shares Issuable Under Amended & Restated Sales Agreement to $50 Mln - SEC Filing

THOMSON REUTERS
·
28 May

Incannex Healthcare Inc. Expands Share Issuance Program with Amended Sales Agreement, Adds $50 Million in Common Stock

Reuters
·
28 May